Hearing Loss

Biotechnology company Sensorion has enrolled the first patient in its Phase IIa Proof of Concept clinical trial of SENS-401 (Arazasetron) in patients suffering from cisplatin-induced ototoxicity.  Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers. A serious side effect of these therapies is ototoxicity, or permanent and irreversible hearing loss, which occurs […]

Biotechnology company Rinri Therapeutics has been awarded an Innovation Passport by the UK Medicines and Healthcare products Regulatory Agency’s (MHRA) for its cell therapy targeting a form of hearing loss.  The Innovation Passport, which is awarded through the MHRA’s Innovative Licensing and Access Pathway (ILAP), will enable Rinri Therapeutics to purse accelerated clinical development and […]